Zealand Pharma A/S (OTCMKTS:ZLDPF) Upgraded at William Blair

Zealand Pharma A/S (OTCMKTS:ZLDPF) was upgraded by William Blair to a “hold” rating in a note issued to investors on Thursday,Zacks.com reports.

ZLDPF has been the subject of a number of other reports. Cantor Fitzgerald upgraded Zealand Pharma A/S to a “strong-buy” rating in a research report on Tuesday, January 21st. JPMorgan Chase & Co. began coverage on Zealand Pharma A/S in a research report on Friday, November 8th. They set an “overweight” rating for the company.

Zealand Pharma A/S Price Performance

Zealand Pharma A/S stock opened at $97.78 on Thursday. The company has a current ratio of 35.49, a quick ratio of 35.49 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $6.94 billion, a PE ratio of -41.43 and a beta of 0.88. Zealand Pharma A/S has a 12 month low of $80.86 and a 12 month high of $141.74. The stock has a 50-day moving average price of $101.00 and a two-hundred day moving average price of $112.64.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last issued its quarterly earnings data on Thursday, February 20th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.19. Zealand Pharma A/S had a negative return on equity of 15.24% and a negative net margin of 1,725.03%. The company had revenue of $1.30 million during the quarter, compared to the consensus estimate of $28.11 million. Analysts expect that Zealand Pharma A/S will post -2.19 EPS for the current year.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.